Summarized by Masters of Longevity from Longevity Technology.
A clinical update on an oral liver-regeneration drug and its progress through an early seamless clinical program; prompts curiosity about next trial steps and broader implications.
Key Takeaways
- The first major liver resection patient completed a 28-day darizmetinib treatment with no treatment-related serious adverse events observed.
- The trial uses a seamless design authorized by FDA, EMA and Israel Ministry of Health to transition into a randomized Phase 2a in the same population.
- Phase 1b second pilot will enroll ten major resection patients and sites in the US, Germany, Spain, France and Israel will support Phase 2a.
